Session

Overview: This session will explore how hypofractionation is transforming prostate radiotherapy, from the biological principles underpinning ultra-short treatment schedules to the practical challenges of implementing them at scale. Landmark clinical trials have established hypofractionation and stereotactic radiotherapy as standards of care, while advances in AI, MRI guidance and adaptive radiotherapy are enabling increasingly precise treatment, with one- or two-fraction curative therapy now within reach for selected patients. The session will also discuss how hypofractionation can improve access to radiotherapy by increasing treatment capacity and reducing patient burden, alongside the education, quality assurance, clinical guidelines and health policies needed for successful implementation.